Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

This Phase II study assessed feasibility and efficacy of a biweekly R-COMP-14 regimen (rituximab, cyclophosphamide, non-pegylated liposome-encapsulated doxorubicin, vincristine and prednisone) in untreated elderly patients with poor-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high ‘li...

Descripción completa

Detalles Bibliográficos
Autores principales: Corazzelli, Gaetano, Frigeri, Ferdinando, Arcamone, Manuela, Lucania, Anna, RosariaVilla, Maria, Morelli, Emanuela, Amore, Alfonso, Capobianco, Gaetana, Caronna, Antonietta, Becchimanzi, Cristina, Volzone, Francesco, Marcacci, Gianpaolo, Russo, Filippo, De Filippi, Rosaria, Mastrullo, Lucia, Pinto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258483/
https://www.ncbi.nlm.nih.gov/pubmed/21707585
http://dx.doi.org/10.1111/j.1365-2141.2011.08786.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258483/
https://www.ncbi.nlm.nih.gov/pubmed/21707585
http://dx.doi.org/10.1111/j.1365-2141.2011.08786.x

Ejemplares similares